• Mashup Score: 3
    Germline EGFR mutations and familial lung cancer - 2 year(s) ago

    BACKGROUND The genomic underpinnings of inherited lung cancer risk are poorly understood. This prospective study characterized the clinical phenotype of patients and families with germline EGFR pathogenic variants (PVs). METHODS The INHERIT study (NCT01754025) enrolled lung cancer patients whose tumor profiling harbored possible germline EGFR PVs and their relatives, either in-person or remotely, providing germline testing and follow-up. RESULTS 141 participants were enrolled over a 5-year period, 100 (71%) remotely. Based upon prior genotyping, 116 participants from 59 kindreds were tested for EGFR T790M, consistent with a pattern of Mendelian inheritance with variable lung cancer penetrance. In confirmed or obligate carriers of a germline EGFR PV from 39 different kindreds, 50/91 (55%) were affected with lung cancer with 34/65 (52%) diagnosed by age 60. Somatic testing of lung cancers in carriers revealed that 35 of 37 (95%) had an EGFR driver co-mutation. Among 36 germline carriers

    Source: ascopubs.org
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of geoff_oxnard
      geoff_oxnard

      Would love to hear more @MattSmeltzer ! Any sign of familial lung nodules? We recently reported on germline EGFR, finding geographic enrichment (and a founder effect!) in US SE: https://t.co/ePItKmqEkH https://t.co/aiURuciYAa

  • Mashup Score: 13
    Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers - 2 year(s) ago

    AbstractPurpose:. Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non–small cell lung cancer (NSCLC); however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimertinib and selpercatinib for RET fusion–mediated osimertinib resistance has not previously been published.Patients and Methods:. Patients who received selpercatinib in combination with osimertinib on a prospective expanded access clinical trial (NCT03906331) and single-patient compassionate use programs across five countries were centrally analyzed. All patients had advanced EGFR-mutant NSCLC with a RET fusion detected from tissue or plasma following osimertinib therapy. Clinicopathologic and outcomes data were collected.Results:. Fourteen patients with EGFR-mutant and RET fusion–positive lung cancers who experienced prior progression on osimertinib received osimertinib and selpercatinib. EGFR exon 19 deletions (±T790M, 86%) and non-KIF5B fusi

    Source: aacrjournals.org
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of geoff_oxnard
      geoff_oxnard

      RT @CCR_AACR: Osimertinib and selpercatinib in EGFR/RET lung cancer. https://t.co/pqPHjMegVl https://t.co/mYMrDFYT72

Load More